Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib

BackgroundOsimertinib is an approved first-line therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, beyond the identification of common EGFR mutations, additional pathological or molecular factors that predict treatment response, survival outcomes...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Walid Shalata, Bilal Krayim, Asmah Miari, Abed Agbarya, Irina Lazarev, Nir Peled, Yulia Dudnik, Ahron Yehonatan Cohen, Amichay Meirovitz, Natalie Maimon Rabinovich, Alexander Yakobson, Firas Abu Akar, Ronen Brenner
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-06-01
Saila:	Frontiers in Molecular Biosciences
Gaiak:	epidermal growth factor receptor non-small cell lung cancer osimertinib overall survival progression-free survival treatment-related adverse events
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fmolb.2026.1878152/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!